Athenex

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Athenex sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Athenex: 10 sponsored US clinical trials, none currently recruiting.

Athenex sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Angiosarcoma of Skin, with 1 trials.

Top-decile sponsor footprint

Athenex ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 2

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

NCT03544567
TERMINATED Phase 1

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03588039
COMPLETED Phase 1

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

NCT03575780
COMPLETED Phase 1

Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies

NCT03987685
COMPLETED Phase 1

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

NCT02730481
COMPLETED Phase 1

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

NCT02337205
COMPLETED Phase 1

Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies

NCT02326441
COMPLETED Phase 1

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

NCT02250157
COMPLETED Phase 2

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

NCT01074138
COMPLETED Phase 1

Evaluation of KX2-391 in Patients With Advanced Malignancies

NCT00658970

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 2

Therapeutic Areas

Angiosarcoma of Skin 1
Actinic Keratosis 1
Solid Tumor 1

How the Athenex early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Angiosarcoma of Skin (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Athenex: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Athenex sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share AthenexAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Athenex sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Athenex sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Athenex page

10 registered trials is a research-attention snapshot, not an endorsement of Athenex or any single study.

  • None of Athenex's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Angiosarcoma of Skin is the condition Athenex studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Angiosarcoma of Skin trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Athenex pipeline card: 10 registered trials from official public datasets.Report a data error.